Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 technology. Operating in the health care sector, CRISPR aims to address serious diseases by editing genes, which could lead to significant advancements in treatment options.

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it indicates the company's profitability and financial health.

$-1.06

Revenue

Revenue figures are important for understanding the company's sales performance and market demand for its therapies.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of $-1.28, which was worse than the expected $-1.14, resulting in a 3.78% increase in stock price the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about CRISPR's upcoming earnings, with expectations for a narrower EPS loss and modest revenue growth. However, the company's history of missing estimates adds uncertainty.

Bull Case

If CRISPR can exceed EPS expectations and show strong revenue growth, it could signal improving operational efficiency and market acceptance of its therapies.

Bear Case

Conversely, if the company misses its EPS and revenue targets again, it may raise concerns about its business model and future profitability.

Key Metrics to Watch

EPS

$-1.06

Earnings per share (EPS) is crucial as it indicates the company's profitability and financial health.

Revenue

$16M

Revenue figures are important for understanding the company's sales performance and market demand for its therapies.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRISPR report an EPS loss narrower than the consensus estimate of $-1.06?

A smaller loss could indicate improved operational efficiency and investor confidence, which is critical for the stock's performance.

What revenue figures will CRISPR report, and how do they compare to the $16M consensus?

Revenue performance is key to assessing market demand for CRISPR's therapies, and any significant deviation could impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CRISPR's potential for a narrower EPS loss due to recent operational improvements not yet reflected in consensus estimates.

Supporting Evidence

The options market is pricing a 26.4% move, indicating significant uncertainty that may not align with the company's actual performance.

Historical trends show that CRISPR has occasionally surprised positively despite recent misses, suggesting potential for a turnaround.

Key Risk

If CRISPR's revenue exceeds $20M, it could significantly shift market perception and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it follows a series of earnings misses, making it critical for restoring investor confidence.

Bull Confirmed If

An EPS loss of $-0.80 or better, along with revenue exceeding $20M, would confirm a positive outlook.

Bear Confirmed If

An EPS loss greater than $-1.50 and revenue below $10M would confirm concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant potential move in CRISPR's stock price following the earnings report, indicating heightened investor uncertainty.

Options price a 26.4% move but the stock has averaged only 3.6% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests a potential stock increase of around 3.6%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity from management.

Miss

If CRISPR misses expectations, history suggests a potential decline of about 0.68%, raising concerns about its operational effectiveness.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of CRISPR's clinical trials and their impact on revenue.
2Details on cost management strategies that could improve EPS performance.
3Insights into market demand for CRISPR's therapies and any new partnerships.
4Management's outlook on future product launches and their expected timelines.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it indicates the company's profitability and financial health.

$-1.06

Revenue

Revenue figures are important for understanding the company's sales performance and market demand for its therapies.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If CRISPR can exceed EPS expectations and show strong revenue growth, it could signal improving operational efficiency and market acceptance of its therapies.

Bear Case

Conversely, if the company misses its EPS and revenue targets again, it may raise concerns about its business model and future profitability.

Key Metrics to Watch

EPS

$-1.06

Earnings per share (EPS) is crucial as it indicates the company's profitability and financial health.

Revenue

$16M

Revenue figures are important for understanding the company's sales performance and market demand for its therapies.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRISPR report an EPS loss narrower than the consensus estimate of $-1.06?

A smaller loss could indicate improved operational efficiency and investor confidence, which is critical for the stock's performance.

What revenue figures will CRISPR report, and how do they compare to the $16M consensus?

Revenue performance is key to assessing market demand for CRISPR's therapies, and any significant deviation could impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CRISPR's potential for a narrower EPS loss due to recent operational improvements not yet reflected in consensus estimates.

Supporting Evidence

The options market is pricing a 26.4% move, indicating significant uncertainty that may not align with the company's actual performance.

Historical trends show that CRISPR has occasionally surprised positively despite recent misses, suggesting potential for a turnaround.

Key Risk

If CRISPR's revenue exceeds $20M, it could significantly shift market perception and expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it follows a series of earnings misses, making it critical for restoring investor confidence.

Bull Confirmed If

An EPS loss of $-0.80 or better, along with revenue exceeding $20M, would confirm a positive outlook.

Bear Confirmed If

An EPS loss greater than $-1.50 and revenue below $10M would confirm concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant potential move in CRISPR's stock price following the earnings report, indicating heightened investor uncertainty.

Options price a 26.4% move but the stock has averaged only 3.6% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests a potential stock increase of around 3.6%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await further clarity from management.

Miss

If CRISPR misses expectations, history suggests a potential decline of about 0.68%, raising concerns about its operational effectiveness.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of CRISPR's clinical trials and their impact on revenue.
2Details on cost management strategies that could improve EPS performance.
3Insights into market demand for CRISPR's therapies and any new partnerships.
4Management's outlook on future product launches and their expected timelines.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.